References
- Mc Elhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, comorbiditiesand frailty are a challenge for the development of more effectiveinfluenza vaccines. Vaccine 2012; 30(12):2060-7; PMID:22289511; http://dx.doi.org/10.1016/j.vaccine.2012.01.015
- Centers for Disease Control and Prevention. Prevention and control of seasonalinfluenza with vaccines. MMWR Recomm Rep 2013; 62(RR-07):1-43.
- Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalentinactivated influenza vaccine in children, adolescents, and adults:A randomized, controlled, phase III trial. Vaccine 2015; 32:2485-92.
- World Health Organization. Recommended viruses forinfluenza vaccines for use in the 2014 northern hemisphere influenza season. Wkly Epidemiol Rec 2010; 85:81-92; PMID:20210260
- State Food and Drug Administration. Guidelines for the classification of adverse reactions to the prevention of clinical trials of vaccines 2005; 493:35-45.
- Peter T, Geoffrey JG, Cynthia BS, Malcolm S, David PG, Ayca OG, Carlos DG, Victoria L. Immunogenicity and safety of Fluzone intradermal and high-dose influenza vaccines in older adults≥65 years of age: a randomized, controlled, phase II trial. Vaccine 2014; 32:2507-17; PMID:24120672; http://dx.doi.org/10.1016/j.vaccine.2013.09.074
- European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). European Agency Evaluation Medicinal Products 1997. p. 26-40.
- FDA. Guidance for industry: clinical data needed to support the licensure ofpandemic influenza vaccines. FDA 2007. p. 1-15.
- Zhao YW, Feng ZJ. The meta analysis on the safety and immunogenicity of domestic and imported split influenza virus vaccines l.Chin. J Vaccines Immun 2014; 15(1):19-26.
- World Health Organization. WHO manual on animalinfluenza diagnosis and surveillance. Geneva: The World Health Organization 2002. p. 1-98.
- Luo FJ, Yang LQ, Ai X, Bai YH, Wu J, Li SM, Zhang Z, Lu M, Li L, Wang ZY, et al. Immunogenicity and safety of three 2010–2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: A double-blind and randomized trial. Hum Vaccin Immunother 2013 2013-08-01; 9(8):1725-34; PMID:23896581; http://dx.doi.org/10.4161/hv.24832
- Williams MS, Wood JM. A brief history of inactivated influenza virus vaccines. Elsevier Science, 1993; 169-71.
- Pyhala R, Haanpaa M, Kleemola M. Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine 2001; 9(23–24):3253-60; http://dx.doi.org/10.1016/S0264-410X(01)00010-X